U.S. CDMRP – Lung Cancer Research Program | Research Funding
Event details
| Date | 23.06.2026 |
| Category | Call for proposal |
| Event Language | English |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 Lung Cancer Research Program (LCRP) Awards. Several award programs are available:
Funding:
Idea Development Award: max. $800K
Patient-Centered Outcomes and Survivorship Award: max. $975K
Translational Research Award: $1.35M – $1.85M
Note: Cost caps are total costs (direct plus indirect costs). In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding
Duration:
Idea Development Award: 3 years
Patient-Centered Outcomes and Survivorship Award: 3 years
Translational Research Award: 3-4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Program-specific seniority levels and eligibility criteria are further defined within each award mechanism here.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline:
Further information:
FY26 LCRP Areas of Emphasis
- The Idea Development Award Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
- The Patient-Centered Outcomes and Survivorship Award Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications.
- The Translational Research Award mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application.
Funding:
Idea Development Award: max. $800K
Patient-Centered Outcomes and Survivorship Award: max. $975K
Translational Research Award: $1.35M – $1.85M
Note: Cost caps are total costs (direct plus indirect costs). In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding
Duration:
Idea Development Award: 3 years
Patient-Centered Outcomes and Survivorship Award: 3 years
Translational Research Award: 3-4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Program-specific seniority levels and eligibility criteria are further defined within each award mechanism here.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline:
- 23 June 2026, 5:00 p.m. Eastern time
- Idea Development Award
- Translational Research Award
- 18 August 2026, 5:00 p.m. Eastern time
- Patient-Centered Outcomes and Survivorship Award
- 02 September 2026, 11:59 p.m Eastern Time
Further information:
- To find the full program announcements and to start your pre-application see here
- A useful summary of each call can be found here
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office
- Grants.gov Funding Opportunity Numbers:
- Idea Development Award: HT942526LCRPIDA
- Patient-Centered Outcomes and Survivorship Award: HT942526LCRPPCOSA
- Translational Research Award: HT942526LCRPTRA
FY26 LCRP Areas of Emphasis
- Biology and Etiology
- Understand the molecular mechanisms of initiation and progression of pre-malignancy to lung cancer.
- Understand contributors to lung cancer development other than tobacco, including hereditary and sex-specific differences.
- Understand the biology of metastatic/oligometastatic disease progression.
- Prevention and Risk Reduction
- Identify innovative strategies for the prevention and/or interception of lung cancer development.
- Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.
- Detection, Diagnosis and Surveillance
- Improve and expand approaches to screening and early detection of lung cancer.
- Identify strategies for prompt detection and/or characterization of progressive disease.
- Treatment and Prognosis
- Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.
- Develop or optimize biomarkers to assist with therapeutic decision-making.
- Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.
- Health Outcomes and Survivorship
- Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on quality of life for patients and families.
- Identify and understand the impact of comorbidities on survivorship care in all stages of lung cancer.
- Reduce differences among high-risk groups and populations.
Practical information
- General public
- Free